TEVA PHARMACEUTICAL INDUSTRIES LTD Quarterly Goodwill in USD from Q1 2010 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
Summary
Teva Pharmaceutical Industries Ltd quarterly Goodwill history and growth rate from Q1 2010 to Q3 2024.
  • Teva Pharmaceutical Industries Ltd Goodwill for the quarter ending September 30, 2024 was $16.1B, a 4.51% decline year-over-year.
Goodwill, Quarterly (USD)
Goodwill, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q3 2024 $16.1B -$761M -4.51% Sep 30, 2024 10-Q 2024-11-06
Q2 2024 $16.5B -$630M -3.68% Jun 30, 2024 10-Q 2024-07-31
Q1 2024 $17B -$792M -4.45% Mar 31, 2024 10-Q 2024-05-08
Q4 2023 $17.2B $0 0% Dec 31, 2023 10-Q 2024-11-06
Q3 2023 $16.9B -$1.55B -8.4% Sep 30, 2023 10-Q 2023-11-09
Q2 2023 $17.1B -$1.72B -9.13% Jun 30, 2023 10-Q 2023-08-02
Q1 2023 $17.8B -$2.19B -10.9% Mar 31, 2023 10-Q 2023-05-10
Q4 2022 $17.2B -$2.86B -14.3% Dec 31, 2022 10-Q 2024-11-06
Q3 2022 $18.4B -$1.75B -8.65% Sep 30, 2022 10-Q 2022-11-03
Q2 2022 $18.8B -$1.58B -7.76% Jun 30, 2022 10-Q 2022-07-27
Q1 2022 $20B -$316M -1.56% Mar 31, 2022 10-Q 2022-05-03
Q4 2021 $20B -$584M -2.83% Dec 31, 2021 10-K 2024-02-12
Q3 2021 $20.2B -$49M -0.24% Sep 30, 2021 10-Q 2021-10-27
Q2 2021 $20.4B -$4.2B -17% Jun 30, 2021 10-Q 2021-07-28
Q1 2021 $20.3B -$4.19B -17.1% Mar 31, 2021 10-Q 2021-04-28
Q4 2020 $20.6B -$4.22B -17% Dec 31, 2020 10-K 2023-02-10
Q3 2020 $20.2B -$4.43B -18% Sep 30, 2020 10-Q 2020-11-05
Q2 2020 $24.6B -$297M -1.19% Jun 30, 2020 10-Q 2020-08-05
Q1 2020 $24.5B -$332M -1.34% Mar 31, 2020 10-Q 2020-05-07
Q4 2019 $24.8B -$71M -0.29% Dec 31, 2019 10-K 2022-02-09
Q3 2019 $24.7B -$2.93B -10.6% Sep 30, 2019 10-Q 2019-11-07
Q2 2019 $24.9B -$2.74B -9.89% Jun 30, 2019 10-Q 2019-08-07
Q1 2019 $24.8B -$3.64B -12.8% Mar 31, 2019 10-Q 2019-05-02
Q4 2018 $24.9B -$3.5B -12.3% Dec 31, 2018 10-K 2021-02-10
Q3 2018 $27.6B -$11.8B -30% Sep 30, 2018 10-Q 2018-11-01
Q2 2018 $27.6B -$12.4B -30.9% Jun 30, 2018 10-Q 2018-08-02
Q1 2018 $28.5B -$16.6B -36.8% Mar 31, 2018 10-Q 2018-05-03
Q4 2017 $28.4B -$16B -36% Dec 31, 2017 10-K 2020-02-21
Q3 2017 $39.4B -$904M -2.24% Sep 30, 2017 6-K 2017-11-02
Q2 2017 $40B +$19.3B +93.4% Jun 30, 2017 6-K 2017-08-03
Q1 2017 $45B +$24.8B +122% Mar 31, 2017 6-K 2017-05-11
Q4 2016 $44.4B +$25.4B +133% Dec 31, 2016 10-K 2019-02-19
Q3 2016 $40.3B +$21.1B +110% Sep 30, 2016 6-K 2016-11-15
Q2 2016 $20.7B +$1.44B +7.49% Jun 30, 2016 6-K 2016-08-04
Q1 2016 $20.3B +$2.34B +13% Mar 31, 2016 6-K 2016-05-09
Q4 2015 $19B +$617M +3.35% Dec 31, 2015 10-K 2018-02-12
Q3 2015 $19.2B +$454M +2.43% Sep 30, 2015 6-K 2015-10-29
Q2 2015 $19.3B +$309M +1.63% Jun 30, 2015 6-K 2015-07-30
Q1 2015 $17.9B -$1.04B -5.5% Mar 31, 2015 6-K 2015-04-30
Q4 2014 $18.4B -$573M -3.02% Dec 31, 2014 20-F 2017-02-15
Q3 2014 $18.7B -$187M -0.99% Sep 30, 2014 6-K 2014-10-30
Q2 2014 $18.9B +$359M +1.93% Jun 30, 2014 6-K 2014-07-31
Q1 2014 $19B +$333M +1.79% Mar 31, 2014 6-K 2014-05-02
Q4 2013 $19B +$125M +0.66% Dec 31, 2013 20-F 2016-02-11
Q3 2013 $18.9B +$242M +1.3% Sep 30, 2013 6-K 2013-10-31
Q2 2013 $18.6B +$220M +1.2% Jun 30, 2013 6-K 2013-08-01
Q1 2013 $18.6B -$67M -0.36% Mar 31, 2013 6-K 2013-05-02
Q4 2012 $18.9B +$563M +3.08% Dec 31, 2012 20-F 2014-02-10
Q3 2012 $18.7B +$2.88B +18.2% Sep 30, 2012 6-K 2012-11-01
Q2 2012 $18.4B +$2.44B +15.3% Jun 30, 2012 6-K 2012-08-02
Q1 2012 $18.7B +$2.91B +18.4% Mar 31, 2012 6-K 2012-05-09
Q4 2011 $18.3B +$3.06B +20.1% Dec 31, 2011 20-F 2014-02-10
Q3 2011 $15.8B +$218M +1.4% Sep 30, 2011 6-K 2011-11-02
Q2 2011 $15.9B +$3.7B +30.3% Jun 30, 2011 6-K 2011-07-28
Q1 2011 $15.8B +$3.24B +25.8% Mar 31, 2011 6-K 2011-05-11
Q4 2010 $15.2B Dec 31, 2010 20-F 2013-02-12
Q3 2010 $15.6B Sep 30, 2010 6-K 2010-11-02
Q2 2010 $12.2B Jun 30, 2010 6-K 2010-07-27
Q1 2010 $12.6B Mar 31, 2010 6-K 2010-05-04
* An asterisk sign (*) next to the value indicates that the value is likely invalid.